Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects
about
Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pharmacokinetics and tolerabil ...... tor KM-023 in healthy subjects
@ast
Pharmacokinetics and tolerabil ...... tor KM-023 in healthy subjects
@en
Pharmacokinetics and tolerabil ...... tor KM-023 in healthy subjects
@nl
type
label
Pharmacokinetics and tolerabil ...... tor KM-023 in healthy subjects
@ast
Pharmacokinetics and tolerabil ...... tor KM-023 in healthy subjects
@en
Pharmacokinetics and tolerabil ...... tor KM-023 in healthy subjects
@nl
prefLabel
Pharmacokinetics and tolerabil ...... tor KM-023 in healthy subjects
@ast
Pharmacokinetics and tolerabil ...... tor KM-023 in healthy subjects
@en
Pharmacokinetics and tolerabil ...... tor KM-023 in healthy subjects
@nl
P2093
P2860
P356
P1476
Pharmacokinetics and tolerabil ...... tor KM-023 in healthy subjects
@en
P2093
Brian Bray
Jae-Yong Chung
Kyoung Soo Lim
Kyung-Sang Yu
Min-Kyu Park
Myung-Chol Kang
Seo Hyun Yoon
Stephen Schneider
Yu-Jung Cha
P2860
P304
P356
10.2147/DDDT.S65596
P407
P50
P577
2014-09-26T00:00:00Z